投资者参考 - 投资者在做出股票买入、卖出或持有决策之前通常会参考华尔街分析师的推荐，但研究表明经纪公司的推荐对指导投资者选择潜力最大的股票并没有太大帮助[4] - 经纪公司对所覆盖股票的利益使得他们的分析师在评级上存在强烈的正向偏见，这导致他们更倾向于给予“强烈买入”推荐，而不是“强烈卖出”[5] Zacks Rank工具 - Zacks Rank是一种可靠的股票评级工具，将股票分为五个等级，从Zacks Rank 1（强烈买入）到Zacks Rank 5（强烈卖出），与ABR相结合可以帮助做出盈利性投资决策[7]

Abbott Laboratories新产品发布 - Abbott Laboratories最近获得FDA批准i-STAT TBI（创伤性脑损伤）试剂盒[1] - 该试验在Abbott的便携式i-STAT Alinity仪器上运行，使用全血帮助评估疑似轻度创伤性脑损伤（mTBI）或脑震荡的患者[1] - 该试验在15分钟内提供实验室质量的结果[1] - Abbott的TBI测试产品线得到了扩展，加强了其诊断业务[1] - i-STAT TBI试剂盒需要少量静脉血样放置在测试卡上，然后放入便携式设备i-STAT Alinity中[2] - 该试验检测大脑中可能释放到血液中的两种生物标志物，指示脑损伤[3] - 使用全血协助评估TBI是Abbott实现目标的关键一步，即使在非医疗环境和更广泛的人群中也可以使用该测试[4] - FDA批准将允许在除了医院急诊科之外的各种新医疗环境中进行测试，包括急诊护理诊所[5] - i-STAT TBI测试可以帮助评估受伤后24小时内的患者，这是一个重大进展[6] Abbott Laboratories市场表现和前景展望 - Verified Market Reports称，创伤性脑损伤治疗市场规模在2023年达到55亿美元，预计到2030年底将达到149亿美元，复合年增长率为12.7%[7] - Abbott在全球范围内在现场测试领域占据重要地位，核心实验室诊断业务得到了加强[8] - Abbott最近获得了新的GLP系统Track实验室自动化系统的FDA批准[9] - 过去一年，ABT的股价上涨了12.6%[10] - Abbott目前持有Zacks Rank 4（卖出）[11] 医疗领域股票推荐 - 其他医疗领域的一些更好的股票包括Stryker Corporation（SYK）、Cencora, Inc.（COR）和Cardinal Health（CAH）[12]

Abbott股票表现 - Abbott (ABT)最新收盘价为$112.09，较上一交易日下跌了1.38%[1] - Abbott股票在过去一个月中下跌了4.18%，表现不如医疗行业的涨幅2.21%和标普500指数的涨幅3.32%[2] Abbott财务预测 - Abbott计划于2024年4月17日公布财报，预计每股收益为$0.96，同比下降6.8%，预计营收为$98.5亿，同比增长1.02%[3] - 分析师预计Abbott全年每股收益为$4.62，营收为$419亿，较去年分别增长4.05%和4.47%[4]

Dividend-paying stocks have generally outperformed those that don't pay dividends over the long term. That's partly because maintaining a healthy dividend requires a solid underlying business. And investors who reinvest those dividends can significantly boost their long-term returns. That said, not every company that pays a dividend is capable of consistency. Many find it necessary in hard times to decrease their payouts or suspend them altogether. Two that are unlikely to do either of those things anytime ...

通货膨胀影响 - 通货膨胀在二月份远高于预期，核心服务通货膨胀率上涨0.5%，导致美联储重新考虑是否过早降息[1] 消费者支出情况 - 消费者支出在一月份下降，家庭债务达到不可持续的17.5万亿美元，信用卡和汽车贷款债务也在创纪录水平上升，个人储蓄仍然疲弱[2] 投资建议 - 个人财务状况糟糕，今年可能会发生衰退，现在是时候调整投资组合以抵御未来的风险。以下三家公司是衰退时值得购买的股票，因为它们具有韧性和下行保护[3]

沃尔玛（Walmart） - 三家公司在面对经济不稳定时表现出色，展现出强大的战略洞察力[1] - 沃尔玛（Walmart）计划在2025年实现净销售额和营业收入的年同比增长[4] - 沃尔玛积极推动电子商务能力提升，国际扩张和技术投资，以推动长期发展[5] - 沃尔玛国际部门的净销售额在不断增长，电子商务收入增长44%，成功进入数字市场[6] - 沃尔玛通过增加年度股息9%来提供价值给股东，ROI和ROA分别达到15.0%和6.6%[7] 宝洁（Procter & Gamble） - 宝洁（Procter & Gamble）通过股票回购和股息支付提高核心每股收益，强调价值传递[9] - 宝洁在多个地区实现了稳健的有机销售增长，市场份额和影响力提升有望继续支持估值和表现[11] 艾伯特实验室（Abbott Labs） - 艾伯特实验室（Abbott Labs）通过多元化的产品组合在多个市场和行业领域保持领先地位[12] - 艾伯特实验室的研发管线提供了超过25个新的增长机会，致力于推出新产品和拓展地理覆盖范围[14]

The latest trading session saw Abbott (ABT) ending at $111.50, denoting a -1.47% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.89%. At the same time, the Dow added 1.03%, and the tech-heavy Nasdaq gained 1.25%. Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 2.98% over the past month. This has lagged the Medical sector's gain of 0.72% and the S&P 500's gain of 3.56% in that time. The upcoming earnings release of Abbot ...

In the latest market close, Abbott (ABT) reached $113.16, with a +0.64% movement compared to the previous day. This change outpaced the S&P 500's 0.57% gain on the day. Elsewhere, the Dow saw an upswing of 0.83%, while the tech-heavy Nasdaq appreciated by 0.39%. The maker of infant formula, medical devices and drugs's shares have seen a decrease of 1.38% over the last month, not keeping up with the Medical sector's gain of 0.13% and the S&P 500's gain of 2.97%. Investors will be eagerly watching for the per ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about Abbott (ABT) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Abbott currently has an average brokerage recommendation (ABR) o ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium also includes the Zacks Style Score ...